| Business

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

J&J wins U.S. approval for TB tablet

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

JNJ $70.10 +$0.62

at close on MONDAY

Daily Photo Galleries

By Anna Edney C.2012 Bloomberg News
Monday, Dec. 31, 2012, 10:30 p.m.

Johnson & Johnson won regulatory approval for its tuberculosis tablet Sirturo, the first drug in 40 years that provides a new way to treat the contagious lung infection.

The Food and Drug Administration cleared Sirturo to be added to therapies for use by adults whose illness is resistant to multiple medicines, the New Brunswick, N.J.- based company said Monday.

While tuberculosis was once the leading cause of death in the nation, the drug-resistant version of the illness affected about 98 people last year, according to the Centers for Disease Control and Prevention.

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Business Headlines

  1. Koppers CEO believes struggling company can do better, transform
  2. More employers adopt generous leave policies
  3. How companies may adjust to tax on employee benefits
  4. States extend $1.5B in breaks for data centers
  5. Credit bureau Experian keeps info on cellular firm’s customers
  6. Anxiety pervades town built by Volkswagen during emissions-cheating scandal
  7. For some small-business owners, fast, short-term loans have unsustainable interest
  8. Small-scale solar power market draws big utilities
  9. Pennsylvania will monitor for earthquake activity linked to fracking
  10. Judge backs Sunoco in dispute over its use of eminent domain
  11. New rules will spare homebuyers from last-minute surprises